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Abstract
Background: This study assessed the survival outcomes and recurrent patterns in pelvic node-positive IB1-IIA2
cervical cancer patients treated with postoperative external beam irradiation with or without vaginal brachytherapy.
Methods: The records of 1149 cervical cancer patients received radical surgery between February 2008 and March
2010 were retrospectively reviewed. 126 stages IB1-IIA2 patients with positive pelvic lymph node (LN) were
included and a total of 113 patients who received different postoperative radiation therapy were identified and
analyzed. Of the enrolled patients, 55 patients received pelvic external beam radiotherapy (EBRT) without vaginal
brachytherapy and 58 patients received pelvic EBRT with vaginal brachytherapy. Treatment-related toxicities were
evaluated. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates and
statistical significance was determined using the log-rank test.
Results: With a median follow-up of 47 months (range: 10–61 months), the group which had pelvic EBRT
with brachytherapy had a significantly improved 5-year PFS rate (P = 0.044), but no significant difference in 5-year
overall survival was found between the two groups (P = 0.437). In patients treated without brachytherapy, the most
common site of relapse was the pelvis. No significant differences were found regards to acute and chronic radiation
toxicities, including myelosuppression, dermatitis, enterocolitis, proctitis and cystitis (P = 0.485, 0.875, 0.671, 0.459 and
0.969 respectively) between the groups of pelvic EBRT with and without vaginal brachytherapy.
Conclusions: Treated with pelvic EBRT in combination with vaginal brachytherapy, cervical cancer patients with
positive pelvic lymph node had a reduced risk of locoregional recurrence without increased side effects compared
with patients treated with pelvic EBRT without vaginal brachytherapy.
Background
Cervical cancer remains one of the most common malig-
nancies in women worldwide and is also a prominent
cause of female cancer death. Treatment for early-stage
disease involves radical hysterectomy (RH) with pelvic
and/or para-aortic lymph node (LN) dissection or radi-
ation therapy (RT) [1], the former of which is used for
most patients because it has the advantage of removing
the primary disease and curing the patient within the
shortest time period possible. Moreover, RH with pelvic
and/or para-aortic LN dissection allows for accurate surgi-
cal staging and more accurately targeted adjuvant therapy
[2]. Following surgery, there are some surgicopathologic
factors that predict disease recurrence. These factors in-
clude primary tumor diameter, depth of stromal invasion,
lymph-vascular space invasion, presence or absence of
parametrial extension, lymph node involvement, and sta-
tus of resection margins [3–5]. Patients with LN metasta-
sis are considered at high risk for recurrence and should
receive postoperative adjuvant therapy [6, 7], such as pel-
vic external-beam radiation therapy with or without vagi-
nal brachytherapy [8, 9]. Several studies have found that
postoperative concurrent chemoradiotherapy can improve
the survival in early-stage cervical cancer patients with
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adverse risk factors by comparing with pelvic radiation
therapy alone as adjuvant therapy [6, 10]. Few studies,
however, have evaluated the outcomes of different adju-
vant therapy strategies for postoperative node-positive pa-
tients with or without vaginal brachytherapy, and standard
postoperative adjuvant therapy has not been established
[11, 12]. Therefore, the aim of this study was to evaluate
the long-term outcomes of cervical carcinoma patients
with positive pelvic lymph nodes underwent pelvic three-
dimensional conformal radiotherapy (3D-CRT) with or
without vaginal brachytherapy and treatment-related tox-




The Institutional Review Board of the Tumor Hospital of
Zhengzhou University reviewed and approved this study
(15CT062) and all study procedures conducted according
to the principles expressed in the Declaration of Helsinki.
A search was performed to identify cervical cancer pa-
tients with FIGO stage IB1-IIA2 disease without evidence
of distant disease who were treated between February
2008 and March 2010 by radical abdominal hysterectomy
and lymphadenectomy with/without bilateral salpingo-
oophorectomy (Fig. 1). A total of 1149 cervical cancer
patients were identified and 1005 patients with negative
pelvic LN and 17 patients with positive para-aortic LN
found by surgical staging or by CT-based scan before pel-
vic external-beam RT were excluded in this study and 126
patients met those criteria finally. Thirteen patients had
incomplete follow-up and were not included in the study.
Of the included 113 patients, 55 patients received pelvic
3D-CRT and concurrent chemotherapy without vaginal
brachytherapy (3D-CRT without brachytherapy group),
and 58 patients were treated with 3D-CRT and concurrent
chemotherapy with a vaginal brachytherapy boost (3D-
CRT with brachytherapy group). Patients with any compo-
nent of serous neuroendocrine or clear cell differentiation
within the tumor and patients with other high risk factors,
including parametrial extension and positive margins, were
excluded from the analyses. The tumor status and general
medical problems of the patients were recorded from their
medical records. Informed consent was signed by all
patients before treatment.
External beam RT
Postoperative radiotherapy was performed within 4 weeks
of radical surgery. The pelvic radiotherapy consisted of a 6
M-volt (MV) X-ray delivered by a linear accelerator using
the anteroposterior parallel opposing technique. Fifty-five
patients who underwent pelvic but not para-aortic node
dissections received whole pelvis irradiation with 3D-
CRT. The median radiation dose was 50 Gy, and it was
delivered to areas at risk for microscopic disease in 1.8 or
2.0 Gy fractions once daily for 5 days per week. The pelvic
treatment fields generally extended superiorly to include
L5. When lateral fields were used, the posterior border
encompassed S2. The clinical target volume (CTV) was
defined as the area of potential microscopic disease and
included the supravaginal portion, cervical stump, para-
cervical tissue, common iliac lymph nodes, internal and
external iliac lymph nodes, obturator lymph nodes, and
sacral lymph nodes.
Intracavitary RT
Fifty-eight patients also received vaginal brachytherapy
weekly during external RT. The prescribed dose was
4–7 Gy per fraction to the proximal 3–4 cm of vaginal
cuff, with a total dose of 10–15 Gy administered in 1–3
fractions with the integrated after loading treatment plan-
ning system. The doses were delivered using high-dose-
rate source iridium-192 with intracavitary vaginal ovoid
applicators. During the treatment, patients were evaluated
weekly by pelvic examination, and complete blood counts
and renal and liver function tests were also performed
weekly.
Concurrent chemotherapy
Patients treated with RT in both groups also received
platinum-based chemotherapy, which consisted of
40 mg/m2 cisplatin weekly.
Follow-up evaluation
After the completion of treatment, patients were evaluated
every 3 months after completion of treatment for the first
year, every 6 months during the following 2 years, and an-
nually thereafter. At each visit, bimanual examination,
physical examination, and vaginal cytology were performed
for the detection of loco-regional recurrence. Ultrasound
Patients received RH
(n = 1149) 
With positive pelvic




brachytherapy (n = 55)
3D-CRT with
brachytherapy (n = 58)
Excluded from this
study (n = 1023)
Incomplete follow-up 
(n = 13)
Fig. 1 Flow chart showing study numbers and reasons for exclusion
in study. The numbers of patients are indicated in parentheses
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or CT scans of the abdomen and pelvic region were
performed. Suspected cases of recurrent disease were con-
firmed by biopsy whenever possible. Progression-free sur-
vival (PFS) was calculated from the date of radiotherapy
initiation to the date of occurrence of disease progression
or the date of last follow-up. Overall survival (OS) was cal-
culated from the date of diagnosis to the date of death or,
for surviving patients, to the date of last follow-up. The
cause of deaths due to disease, directly or indirectly from
treatment-related complications, and unknown causes that
occurred less than five years after treatment was confirmed
by correspondence, telephone or medical record review.
Surviving patients were censored on the date of last
follow-up. Sites of recurrence were classified as pelvic or
extrapelvic. Pelvic recurrence was further classified as re-
currence in the central or peripheral pelvic wall. Extrapel-
vic sites of recurrence included the paraaortic lymph nodes
and other sites, such as the supraclavicular lymph nodes
and viscera.
Statistical analysis
OS and PFS were calculated using the Kaplan-Meier
method. Differences between groups were analyzed using
the log-rank statistic. The clinical characteristics of the pa-
tients, local control, survival, toxicities, and the dosimetric
parameter were considered categorical variables and were
compared between the two groups using the Student t test
and X 2 test. Statistical significance was defined at a level
of P < 0.05. All analyses were performed using SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL).
Results
Patient and tumor characteristics
Amount the 1149 patients who received Piver type III rad-
ical hysterectomy and lymphadenectomy with/without bi-
lateral salpingo-oophorectomy, 126 patients (10.9 %) were
found had pelvic lymph note metastasis. The demographics
and clinical characteristics of the patients in this study are
summarized in Table 1. The median age of the patients in
3D-CRT without brachytherapy group was 49 years (range
26–73) and the median age of the patients in the 3D-CRT
with brachytherapy group was 50 years (range 27–76).
There were no statistically significant differences in terms
of age, tumor stage, histology, grade, number of dissected
lymph nodes and number of positive lymph nodes.
Clinical outcomes
The median follow-up for patients was 47 months (range:
10–61 months). All time intervals were measured from
the time of diagnosis. In the 3D-CRT without brachyther-
apy group, at the time of the last follow-up, 41 of 55 pa-
tients were alive without evidence of disease, 14 patients
had experienced recurrence, and nine patients had died.
Of the 14 patients with recurrence, ten patients had pelvic
recurrence, including six patients with vaginal recurrence,
four patients failed with pelvic recurrence, one with para-
aortic region recurrence and three patients had distant
failure. In 3D-CRT with brachytherapy group, at the time
of the last follow-up, 52 of 58 patients were alive without
evidence of disease and six patients had experienced
recurrence. Of the patients with recurrent, five patients
experienced distant failure and died from cervical cancer,
and only one patient experienced peripheral pelvic wall
recurrence.
A statistically significant difference in PFS was ob-
served between the different adjuvant treatment groups.
The 5-year PFS rate was higher in patients treated with
3D-CRT with brachytherapy than in those treated with
3D-CRT only; the PFS at 5 years was 71.1 % in the
combined-therapy group and 55.1 % in the 3D-CRT
alone group according to the Kaplan-Meier analysis, and
this difference was statistically significant (P = 0.044)
(Fig. 2a). The 5-year OS rate for the patients treated with
and without vaginal brachytherapy were 72.1 and 64.3 %,
respectively, and this difference was not statistically sig-
nificant (P = 0.437) (Fig. 2b).
Acute and chronic radiation toxicities
No treatment-related deaths were observed. Acute and
chronic toxicities were assessed using the Acute Radiation
Morbidity Scoring Criteria and the Late Radiation









Age (years, median) 49 (26–73) 50 (27–76) 0.313
FIGO stage 0.947
IB1 11 (20.0 %) 9 (15.5 %)
IB2 13 (24.6 %) 15 (25.9 %)
IIA1 19 (34.5 %) 24 (41.4 %
IIA2 12 (21.8 %) 10 (17.2 %)
Histology 0.785
Squamous cell carcinoma 47 (85.5 %) 51 (87.9 %)
Adenocarcinoma 8 (14.5 %) 7 (12.1 %)
Grade 0.719
1 8 (14.5 %) 9 (15.5 %)
2 30 (54.4 %) 33 (56.9 %)
3 17 (30.9 %) 16 (27.6 %)
Number of retrieved lymph
nodes
24.9 ± 4.2 24.7 ± 3.7 0.825
Number of positive lymph
nodes
1
≤3 51 (92.7 %) 53 (96.4 %)
>3 4 (7.3 %) 5 (3.6 %)
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Morbidity Scoring Scheme of the RTOG. Toxicities that
occurred more than 3 months after the start of radiother-
apy were considered as late toxicities. The major acute
reactions observed included myelosuppression, proctitis,
dermatitis bellyache, diarrhea, and acute cystitis. Mye-
losuppression was the most common undesirable side
effect for both groups. No significant differences were
found in leukopenia, dermatitis, enterocolitis, proctitis
and cystitis between the two groups (P = 0.485, 0.875,
0.671, 0.459 and 0.969 respectively), as shown in Table 2.
Discussion
Women with cervical cancer detected at the early stage are
often treated with radical hysterectomy (RH) combined
with pelvic and/or para-aortic lymph node (LN) dissection.
After surgery, several prognostic factors indicate the need
for additional treatment, including parametrial involve-
ment, vaginal invasion, positive pelvic lymph nodes, lymph-
vascular-space invasion, deep stromal invasion, and tumor
size, and the former three are defined as high risk factors
that necessitate adjuvant radiotherapy [3–5]. The presence
of positive pelvic lymph nodes was the most frequently
encountered high risk factor, and it is always considered an
independent prognostic factor [6–9]. Uno et al. found that
Fig. 2 Kaplan-Meier survival curves of progression free survival (PFS)
and overall survival (OS): (a) PFS; (b) OS
Table 2 Incidences of acute and late toxicities in groups given











0 6 (10.9 %) 9 (15.5 %)
1 15 (27.3 %) 17 (29.3 %)
2 22 (40.0 %) 20 (34.5 %)
3 9 (16.4 %) 10 (17.2 %)
4 3 (5.5 %) 2 (3.4 %)
Dermatitis 0.875
0 31 (56.4 %) 34 (58.6
1 20 (36.4 %) 19 (32.8 %)
2 4 (7.3 %) 5 (8.6 %)
3 0 (0 %) 0 (0 %)
4 0 (0 %) 0 (0 %)
Enterocolitis 0.671
0 32 (58.2 %) 33 (56.9 %)
1 20 (36.4 %) 18 (31.0 %)
2 3 (5.5 %) 6 (10.3 %)
3 0 (0 %) 1 (1.7 %)
4 0 (0 %) 0 (0 %)
Late side effect
Proctitis 0.459
0 30 (54.5 %) 29 (50.0 %)
1 18 (32.7 %) 23 (39.7 %)
2 7 (12.7 %) 8 (13.8 %)
3 0 (0 %) 1 (1.7 %)
4 0 (0 %) 0 (0 %)
Cystitis 0.969
0 34 (61.8 %) 35 (60.3 %)
1 14 (25.5 %) 15 (25.9 %)
2 7 (12.7 %) 6 (10.3 %)
3 1 (1.8 %) 2 (3.4 %)
4 0 (%) 0 (0 %)
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the 5-year OS rates for patients with and without pelvic
lymph node metastasis were 52 and 89 %, respectively, and
the relapse-free survival rates for those patients were 44
and 83 %, respectively [13]. Stock RG et al. reported that
patients who received postoperative whole pelvic irradiation
had significantly improved pelvic control, disease-free sur-
vival, and overall survival rates [8]. However, most patients
with LN metastasis received adjuvant postoperative radio-
therapy and platinum-based chemotherapy without vaginal
brachytherapy, and intracavitary radiotherapy was only
combined with external-beam radiotherapy at some institu-
tions and only in cases with involved vaginal resection mar-
gins [14, 15]. Few studies have assessed the postoperative
survival outcomes of patients with pelvic lymph node me-
tastasis with/without brachytherapy. Therefore, the current
study investigated the impact of vaginal brachytherapy in
patients with pelvic lymph node metastasis after RH and
attempted to determine whether brachytherapy was neces-
sary in these patients [16, 17] .
In this retrospective study, we compared the DFS of
patients with pelvic lymph node metastasis who received
pelvic external beam radiotherapy with brachytherapy
postoperatively to those of patients who received pelvic
EBRT alone. The Kaplan-Meier survival analysis demon-
strated that PFS differed significantly between these two
groups. The 5-year progression-free survival rate was
higher in patients treated with 3D-CRT combined with
vaginal brachytherapy than in those treated with pelvic
EBRT alone. Patient prognosis and the pattern of treat-
ment failure correlated with the method of treatment.
Patients in the combined group had less local progres-
sion than those in the group given pelvic EBRT alone.
For patients who received pelvic RT only, the most com-
mon first site of relapse was the pelvis; in contrast, only
one of the patients treated with external beam RT plus
brachytherapy experienced pelvic recurrence, suggesting
that pelvic EBRT alone is not adequate to prevent local
recurrence.
Intracavitary brachytherapy involves the application of a
radioactive source in close proximity to the upper part of
vaginal cuff, which allows for a high dose to the tumor
bed with relative sparing of the surrounding normal struc-
tures and are often given after EBRT is completed. As
Kim et al. found that among patients who had received
postoperative radiotherapy, 41 % failed in the pelvis, and
mainly at vaginal wall and vaginal cuff, which partly ex-
plains the improved PFS at combined treatment group in
the current study [18]. The benefit of vaginal cuff brachy-
therapy can also be found in other type of gynecological
cancer, for example, the results of Low’s study found that
adjuvant chemotherapy, EBRT, and vaginal brachytherapy
for high risk endometrial cancer patients demonstrated
15 % pelvic recurrence and 0 % vaginal recurrence [19].
The reduction in local recurrence with the addition of
brachytherapy will benefit a larger number of patients at
high-risk and will result is a higher DFS rate [7, 20].
To maximize PFS while minimizing treatment-related
morbidity, it is important to determine the risks and
benefits of adjuvant RT and chemotherapy after radical
surgery for each patient individually. Although complica-
tions are often underreported in retrospective reports,
the majority of patients are able to finish the prescribed
radiation regimen, including both external beam radi-
ation and brachytherapy, and most patients undergo ra-
diation therapy with minimal side effects. The rates of
acute and late complications in our study were acceptable
and comparable to those of previous reports, such as a re-
port by Sedlis of severe and life-threatening toxicities in
6 % of irradiated patients [21]. Moreover, side effects at
bladder or rectum with the addition of brachytherapy were
not significantly to the recorded doses. These results indi-
cate that the combination of adjuvant therapy with brachy-
therapy was well-tolerated and that this treatment regimen
should be recommended as a more effective method for
postoperative adjuvant RT in node-positive cervical cancer
patients. However, the reported rate of brachytherapy use
was lower than expected, as the equipment and number of
staff were insufficient to perform brachytherapy in some
gynecologic oncology departments, especially in small
non-academic institutions [22, 23].
In conclusion, we observed that the combination of pelvic
EBRT and concomitant chemotherapy with vaginal brachy-
therapy was more effective for the treatment of pelvic
node-positive cervical cancer than pelvic EBRT and con-
comitant chemotherapy alone. The inclusion of brachyther-
apy reduced the local recurrence rate of cervical cancer,
which led to a higher disease-free survival rate, and did not
increase the rates of side effects, such as hematologic tox-
icity. Additionally, the incidence of late side effects was
similar between the two treatment groups. This preliminary
study suggests that pelvic EBRT with vaginal brachytherapy
is feasible and may have significant clinical implications for
cervical cancer treatment; therefore, brachytherapy should
be considered in future treatment strategies for pa-
tients who are candidates for post-irradiation RT after
surgical treatment.
The limitations of our study include the methodological
uncertainties of the diagnostic procedures and the rela-
tively low number of patients available for assessment.
There are also several limitations in this study. Firstly, dif-
ferent types of radical hysterectomy were not compared,
and para-aortic LN dissection was not performed rou-
tinely, which is also a prognostic factor for PFS and OS.
Secondly, no concrete treatment policy about addition of
brachytherapy has been build, which make the adding of
brachytherapy depending the discretion of the gynecologic
oncologist. Moreover, due to the retrospective design of
this study, recall bias is likely to exist. Therefore future
Li et al. Radiation Oncology  (2015) 10:189 Page 5 of 6
prospective clinical trials are needed to validate the results
of the current study and to evaluate the most effective RT
doses for the treatment of cervical cancer patients.
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